BNT-167
/ Pfizer, BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 30, 2022
BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
(GlobeNewswire)
- "Shingles Vaccine Program...Pfizer and BioNTech signed a new global agreement to develop the first mRNA-based shingles vaccine candidate....Clinical trials are planned to start in the second half of 2022."
New trial • Herpes Zoster • Infectious Disease
1 to 1
Of
1
Go to page
1